((自动化翻译由路透提供，请见免责声明 )) (更正简报来源为欧洲药品管理局，而非默克公司)
路透10月4日 - 欧洲药品管理局(EMA)：
* EMA：在对自杀意念和行为表示担忧后，已开始对含有非那雄胺和度他雄胺的药物进行审查
* EMA：最近，在丙磺舒和丙磺舒的产品信息中，自杀意念也被列为一种可能的副作用，发生频率不详
* 环境管理署：直接与医护专业人员沟通，告知医护专业人员凯帕拉和左乙拉西坦潜在的用药错误风险
* EMA：因改变定量注射器的容量而导致开普拉和左乙拉西坦的用药错误
Eikon 的源文本： 更多公司报道：
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.